January 2018

Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Author:  Michael Millhollen
Posted:  08 January 2018

As announced earlier this month, Sekisui XenoTech has hired a record number of new staff over the past year in order to meet current demand for our drug discovery & development products and services. Several previous employees also returned to the company. The new staff span Sekisui XenoTech’s contract research, quality assurance, business, IT, and other departments.
 
“Our hiring efforts are a reflection of our commitment to maintaining strict quality standards while meeting client needs and timelines,” explained Toshinari Ohara, PhD, CEO of Sekisui XenoTech. He added, “2017 ties 2011 for our second-highest number of new hires in a single year.”

Dr. Ohara continued, “Geographically, North America has seen the most sales growth in the last year, which we expect to continue in 2018. We have seen strong demand across all of our research service areas, although a particularly high percentage of recent inquiries have focused on our drug-drug interaction expertise following the new FDA and PMDA DDI guidance documents. In fact, our recent webinar on the subject commanded 4x higher attendance than many of our past webinars. We have also seen strong demand across our in vitro test system offerings. In particular, requests for our CryostaX® hepatocytes increased following the recently awarded patent, as have orders for our Research Biobank disease-defined liver tissue preparations because of their value for NASH research.”
 
Darren Warren, PhD, COO of Sekisui XenoTech added, “We are anticipating 10% or higher growth for at least the next couple of years. Considering our long-standing DDI expertise and the FDA, PMDA and upcoming EMA guidance, drug-drug interaction studies and consulting will likely remain in particularly high demand. We will also be announcing new test system products based on the demand for both legacy and recently introduced products as well as the custom preparation requests that we have been receiving.”

Read the press release
View our current open positions
Learn more about our products and services

Comments
Blog post currently doesn't have any comments.
Give Feedback